Moderna Raises Annual Revenue Forecast on Strong Overseas COVID Vaccine Demand

Moderna's upward revision of its annual revenue forecast indicates stronger-than-expected overseas demand for its COVID vaccine and supports the fundamental outlook in the near term. The price has risen 9.6% over the past 24 hours, moving above both the SMA20 and SMA50; with an RSI of 57, it remains far from overbought territory, suggesting momentum has not yet exhausted. The MACD is slightly above its signal line and in positive territory, confirming that the short-term trend is upward. However, some of the news-driven jump may already be priced in; I expect a moderate upward bias over the 1-3 day horizon, with additional confirmation needed for a sharp rally. Overall, the direction is upward, with moderate confidence.

The news headline concerns Moderna and has no direct link to GOOGL’s fundamental dynamics. Consequently, the story is not expected to generate a clear short‑term directional move for GOOGL. Technical indicators provide a mixed signal: the RSI sits at 46, in the neutral‑weak zone; the MACD is slightly above the signal line yet remains negative; price is trading below the 20‑period SMA and near the 50‑period SMA. Despite a 1.5% rise over the past 24 hours, momentum is weak, so the outlook is horizontal. With no catalyst from the news, the directional forecast remains neutral.